Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nuron Biotech has licensed its HibTITER vaccine to Mitsubishi Tanabe Pharma for commercialization in the Japanese market for both the single entity and for combination product use.
Subscribe to our email newsletter
Under the agreement Mitsubishi is responsible for any necessary development and regulatory approval costs, pay undisclosed upfront, pre-commercial milestones and pay Nuron significant royalties on commercial sales in Japan.
Nuron acquired HibTITER (Haemophilus b Conjugate Vaccine (Diphtheria CRM197 Protein Conjugate)) from Wyeth, a wholly owned subsidiary of Pfizer.
HibTITER was one of the first glycoconjugate technology vaccines for humans on the market and was responsible for reducing the incidence of Hib disease in children.
Nuron CEO Shankar Musunuri said the agreement provides them with additional resources to accelerate their re-launch strategy of the vaccine in the US market.